Literature DB >> 9394031

Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.

L L Koenigs1, R M Peter, S J Thompson, A E Rettie, W F Trager.   

Abstract

The P450 2A6 catalyzed 7-hydroxylation of coumarin proceeded with a mean Km of 0.40 (+/-0.13) microM and Vmax of 6.34 nmol/nmol P450/min (36-fold variation) in microsomal preparations from a panel of 12 human livers. Substrate depletion was avoided during the kinetic determinations. 8-Methoxypsoralen (8-MOP) is a potent mechanism-based inactivator of human liver P450 2A6 and reconstituted purified recombinant P450 2A6 based on the following evidence: 1) 8-MOP causes time, concentration, and NADPH-dependent loss of P450 2A6 activity that is not reversed by potassium ferricyanide or extensive dialysis, 2) loss of P450 2A6 activity is associated with a loss of spectrally observable P450, 3) addition of nucleophiles or reactive oxygen scavengers to the incubations does not prevent inactivation of P450 2A6, and 4) 8-MOP-dependent P450 2A6 inactivation is inhibited (concentration dependent) by the addition of a competitive inhibitor (pilocarpine). Inactivation is selective for P450 2A6 at low concentrations of 8-MOP (2.5 microM) after short incubation time periods (3 min) and was characterized by a KI of 0.8 and 1.9 microM in a reconstituted and microsomal system, respectively, and a kinact of 1 min-1 and 2 min-1 in a reconstituted and microsomal system, respectively. A substrate depletion partition ratio of 21 was calculated for the inactivation of recombinant P450 2A6. Potency and selectivity suggest that 8-MOP could be a useful tool in vitro for evaluating P450 2A6 activity in various enzyme preparations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394031

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  Contamination of deconjugation enzymes derived from Helix pomatia with the plant bioactive compounds 3,3'-diindolylmethane, 5-methoxypsoralen, and 8-methoxypsoralen.

Authors:  Cheryl E Ainslie-Waldman; Scott W Simpkins; Pramod Upadhyaya; Steven G Carmella; Stephen S Hecht; Sabrina P Trudo
Journal:  Food Chem Toxicol       Date:  2013-08-30       Impact factor: 6.023

3.  Binding free energies for nicotine analogs inhibiting cytochrome P450 2A6 by a combined use of molecular dynamics simulations and QM/MM-PBSA calculations.

Authors:  Haiting Lu; Xiaoqin Huang; Mohamed Diwan M AbdulHameed; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2014-03-03       Impact factor: 3.641

4.  Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.

Authors:  Xin Zhou; Jaime D'Agostino; Fang Xie; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2012-01-19       Impact factor: 4.030

5.  Metabolism of bupropion by baboon hepatic and placental microsomes.

Authors:  Xiaoming Wang; Doaa R Abdelrahman; Valentina M Fokina; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Biochem Pharmacol       Date:  2011-05-05       Impact factor: 5.858

6.  Inhibition of CYP6B1-mediated detoxification of xanthotoxin by plant allelochemicals in the black swallowtail (Papilio polyxenes).

Authors:  Zhimou Wen; May R Berenbaum; Mary A Schuler
Journal:  J Chem Ecol       Date:  2006-03-30       Impact factor: 2.626

7.  Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.

Authors:  Yune-Fang Ueng; Chien-Chih Chen; Yu-Ting Chung; Tsung-Yun Liu; Yu-Ping Chang; Wei-Sheng Lo; Norie Murayama; Hiroshi Yamazaki; Pavel Souček; Gar-Yang Chau; Chin-Wen Chi; Ruei-Ming Chen; Ding-Tzai Li
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 8.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

9.  A suite of activity-based probes for human cytochrome P450 enzymes.

Authors:  Aaron T Wright; Joongyu D Song; Benjamin F Cravatt
Journal:  J Am Chem Soc       Date:  2009-08-05       Impact factor: 15.419

10.  Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes.

Authors:  N M DeVore; B D Smith; J L Wang; G H Lushington; E E Scott
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.